Cagrisema（Cagrilintide/semaglutide） NEW

CagriSema: A Novel Combination Therapy for Weight Management and Glycemic Control

CagriSema is a combination medication consisting of cagrilintide (an amylin analog) and semaglutide (a GLP-1 receptor agonist), both at 2.4 mg doses, administered once weekly for the treatment of obesity and type 2 diabetes.

Mechanism and Composition

CagriSema combines two distinct mechanisms of action:

• Cagrilintide (2.4 mg): A long-acting amylin analog that works through amylin receptors

• Semaglutide (2.4 mg): A GLP-1 receptor agonist with established weight loss and glycemic benefits

This combination is administered as a once-weekly subcutaneous injection, with both components at 2.4 mg doses.

Clinical Efficacy

Weight Management

• In adults with obesity or overweight without diabetes, CagriSema demonstrated a mean weight reduction of 20.4% from baseline after 68 weeks compared to 3.0% with placebo 1

• Significantly more patients achieved weight loss targets:

• 5% or more weight loss

• 20% or more weight loss

• 25% or more weight loss

• 30% or more weight loss

Type 2 Diabetes

• In adults with type 2 diabetes and obesity/overweight, CagriSema produced a mean weight reduction of 13.7% compared to 3.4% with placebo after 68 weeks 2

• 73.5% of patients receiving CagriSema achieved HbA1c levels of 6.5% or less compared to 15.9% in the placebo group 2

• CagriSema demonstrated a 2.2 percentage point reduction in HbA1c compared to a 0.9 percentage point reduction with cagrilintide alone in a phase 2 trial 3

Glycemic Control Benefits

• Time in range (3.9-10.0 mmol/L) improved from 45.9% at baseline to 88.9% at week 32 with CagriSema in a phase 2 trial 3

• Mean fasting plasma glucose reduction of 3.3 mmol/L with CagriSema compared to 1.7 mmol/L with cagrilintide alone 3

Unique Metabolic Effects

CagriSema appears to preserve energy expenditure while reducing energy intake, which may contribute to its enhanced weight loss effects compared to either component alone:

• In animal studies, CagriSema produced 12% weight loss with a 39% reduction in food intake, while weight-matched controls required a 51% decrease in food intake 4

• Approximately one-third of CagriSema's weight loss efficacy appears to come from blunting metabolic adaptation 4

• 
  

Hello ,dear Sir/Madam

thanks for your time 

I would like to send you the price list and COA ,pictures to check 

Pls contact:

Email:    frank88rawpowder@outlook.com

Tel/WA: 852 4642 4790

China Bigbull Chemical lab